Dr. Dudley is director of cell products in the technical R&D group of the Novartis cell and gene therapy unit (TRD-CGTU) in Cambridge, Massachusetts. He leads collaborative process development activities between Novartis and academic research partners in Chimeric Antigen Receptor T Cell (CART) projects, including new targets, gene editing approaches, automation and technology evaluation. He brings deep process, analytic, and product knowledge to the Novartis CGTU team for global technology transfer, analytics harmonization, risk analysis and regulatory compliance activities. As a member of the TRD-CGTU leadership team, he is responsible for articulating the vision for future CGTU platforms and implementing solutions to current process bottlenecks.
Before joining Novartis, Dr. Dudley served at the U.S. National Cancer Institute where he was the director of the cell production facility and specialized in production of autologous cell and gene therapies. He is the author or co-author of more than 100 refereed journal articles and an inventor on several patents. Mark obtained a Ph.D. in biological sciences from Stanford University and a B.S. in biology from the Massachusetts Institute of Technology.
